Conditions we treat
Ketamine for OCD: What Early Research Suggests
Research on ketamine for obsessive-compulsive disorder is early and limited. What studies suggest, what they do not, and how candidacy works.
Understanding OCD and its standard treatments
Obsessive-compulsive disorder involves unwanted, intrusive thoughts (obsessions) and repetitive behaviors or mental rituals (compulsions) that can consume hours of a person's day. It is a real and often disabling condition — not a personality quirk or a preference for tidiness.
According to the National Institute of Mental Health, the best-supported treatments are serotonin reuptake inhibitor medications (SSRIs) and a specific form of cognitive behavioral therapy called exposure and response prevention, or ERP. Many people improve with these approaches, but some continue to have significant symptoms despite trying them.
What early ketamine research suggests — and what it does not
A small number of early studies have explored whether ketamine may influence obsessive-compulsive symptoms. The evidence so far is preliminary: studies are few, small, and short, and ketamine is not FDA-approved for OCD.
It would be wrong to read early research as a promise. Nobody yet knows which OCD patients, if any, benefit reliably, how long any benefit might last, or how ketamine compares with simply adjusting standard treatment. We will describe the science to you exactly as it stands.
Why standard treatments come first
Because SSRIs and ERP have far stronger support, they remain the starting point — and usually the second and third steps too, with adjustments in medication, dose, or therapy approach. Ketamine may be considered only in select cases, after standard treatments have genuinely been tried, and with coordination between our clinicians and the specialists already involved in your care.
- Off-label and early-stage: never a first-line option for OCD
- Considered only after adequate trials of standard treatments
- Coordinated with your psychiatrist or therapist, never around them
How candidacy is evaluated
An evaluation looks at the full picture: how OCD has affected your life, which treatments you have tried and for how long, your medical history, and your current medications. Some medical and psychiatric histories rule ketamine out entirely.
If ketamine therapy may be worth considering, we explain the reasoning and the unknowns. If it is not a good fit — or if a further adjustment to standard care makes more sense — we say so plainly.
Safety and supervision
Ketamine can cause short-term side effects, including dissociation, nausea, and blood pressure changes, and the FDA has warned about risks tied to compounded ketamine products used without adequate safeguards. Any treatment here happens in a monitored clinical setting, with screening beforehand and follow-up planning afterward.
OCD can be deeply distressing, and some people with OCD also experience depression or thoughts of self-harm. If you are in crisis now, call or text 988 (Suicide & Crisis Lifeline) or call 911 — do not use this website for urgent help.
Common questions
No. Ketamine is FDA-approved as an anesthetic, and esketamine (Spravato) is approved for specific depression indications — but no ketamine product is FDA-approved for OCD. Any use for OCD is off-label, which is why careful evaluation and supervision matter.
No. Exposure and response prevention and SSRIs remain the best-supported OCD treatments. If ketamine is ever considered, it is as an addition to ongoing standard care — not a substitute for it — and your existing providers stay involved.
Early and limited. Only a small number of studies exist, they are small, and their results are preliminary. We will walk you through what the research actually shows — and what it cannot show — before any decision is made.
Only select cases — typically adults whose OCD remains severe despite adequate trials of standard treatments, and only with specialist coordination. A clinical evaluation is the only way to know whether that applies to you.
Sources & further reading
- Obsessive-Compulsive Disorder (OCD) — National Institute of Mental Health. Accessed 2026-07-23. Overview of OCD and standard treatments including SSRIs and ERP.
- FDA warns patients and health care providers about potential risks associated with compounded ketamine products — U.S. Food and Drug Administration. Accessed 2026-07-23.
- 988 Suicide & Crisis Lifeline — Substance Abuse and Mental Health Services Administration. Accessed 2026-07-23.
Links point to external organizations. Clear Ketamine Therapy does not control their content.
Keep reading
- Am I a Candidate?Candidacy for ketamine therapy depends on your diagnosis, treatment history, health, and medications. Learn the factors clinicians weigh — and the next step.
- Safety & Side EffectsThe full safety picture: common short-term side effects, who should not receive ketamine, the FDA's compounded-ketamine warning, and our monitoring practices.
- What to ExpectA plain-language walkthrough of the full treatment process at our Tampa clinic — the evaluation, the sessions themselves, and the follow-up — including the parts that vary from person to person.
- Ketamine Therapy TampaPhysician-supervised ketamine therapy for adults in Tampa, Florida — what it is, who it may help, and how to take the first step.
Talk with our clinical team
A consultation is a conversation, not a commitment. Ask questions, share what you are comfortable sharing, and learn whether ketamine therapy may be worth considering for you.
Not for emergencies — call or text 988 or 911 if you are in crisis.